Dr. Melissa Wilson discusses new treatments in the field of pulmonary hypertension in 2024, focusing on Sotatercept and combination therapy with Opsynvi. Dr. Wilson emphasizes the importance of patient selection and individualized treatment plans. She also discusses the initiation and monitoring of these therapies, as well as potential side effects and patient adherence.
Claim your 0.5 CME credits for listening to this episode here: https://forms.gle/42yHmF8UpemVhdDJA.
Visit our website for more APP Pulmonary, Critical Care, and Sleep Medicine content and free CMEs www.pulmapp.com
Follow us on:
